Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, ...

ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...

Data at ASH 2025 highlighted that standardized workflows, education, monitoring innovations, and collaboration are steadily ...

ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular ...

Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases.

Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free ...

Optimizing bispecific AE management in the community requires a combination of standardized clinical protocols, reliable educational tools, and robust communication networks with academic partners.

A Maui Derm 2026 session explored advancements in pediatric dermatology, emphasizing precision medicine and targeted therapies for children.

Remibrutinib, a BTK inhibitor, offers a new oral treatment for chronic spontaneous urticaria, providing an alternative to traditional therapies. Experts discuss groundbreaking therapies in dermatology ...

Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting ...

The American Academy of Pediatrics (AAP) released its 2026 child and adolescent immunization schedule, which continues to ...

To set the stage for this milestone issue, Apathy reflects on the most significant health IT advancements of the past 15 ...